Sol-Gel Technologies Ltd. logo
Sol-Gel Technologies Ltd. SLGL
$ 44.03 0.07%

Annual report 2024
added 12-13-2025

report update icon

Sol-Gel Technologies Ltd. Financial Ratios 2011-2025 | SLGL

Annual Financial Ratios Sol-Gel Technologies Ltd.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-1.2 -1.0 -4.3 49.9 -7.5 -10.2 -3.3 -0.5 - - - - - -

P/S

- - - 5.1 25.0 10.9 829.7 99.4 - - - - - -

EPS

-0.4 -1.0 -0.7 0.1 -1.3 -1.3 1.8 5.0 3.3 1.5 - - - -

EV (Enterprise Value)

- - - 154 M 221 M 250 M 107 M 80.3 M 35.3 M 19.8 M - - - -

EBITDA per Share

- - - 0.17 -1.3 -1.28 -1.83 -4.95 - - - - - -

EV/EBITDA

34.3 -7.3 -9.8 -3.1 - - - - - - -

PEG

- 2.36 -0.34 1.3 - - - - - - -

P/B

0.5 0.7 1.5 2.9 4.3 4.8 1.7 -0.3 - - - - - -

P/CF

-0.9 -1.5 -6.7 -20.9 -8.7 -11.1 -4.6 -0.7 - - - - - -

ROE %

-36.67 -70.48 -35.35 5.79 -57.60 -46.91 -50.39 59.90 - - - - - -

ROA %

-29.52 -60.15 -32.00 4.66 -49.51 -40.14 -46.21 -206.12 - - - - - -

ROCE %

-39.31 -71.89 -37.52 5.16 -56.83 -47.36 -51.74 60.96 - - - - - -

Current Ratio

5.1 6.8 10.6 5.1 7.1 6.9 12.1 0.2 - - - - - -

DSO

- - - 88.8 130.5 32.8 - - - - - - - -

Operating Cycle

- - - 88.8 130.5 32.8 - - - - - - - -

Cash Conversion Cycle

- - - 88.8 130.5 32.8 - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Sol-Gel Technologies Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

- - - - - - 0.35 - - - 0.31 - - - 0.26 - - - 0.36 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- - - - - - -0.35 - - - -0.33 - - - -0.28 - - - -0.38 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

- - -20.47 -40.94 -40.94 -20.47 -31.26 -21.58 -21.58 -10.79 -19.79 -18.00 -18.00 -9.00 -17.47 -16.94 -16.94 -8.47 -8.47 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

- - -17.31 -34.62 -34.62 -17.31 -26.78 -18.95 -18.95 -9.47 -17.25 -15.54 -15.54 -7.77 -7.77 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

- - -19.50 -38.99 -38.99 -19.50 -30.65 -22.30 -22.30 -11.15 -20.58 -18.87 -18.87 -9.43 -18.37 -17.87 -17.87 -8.93 -8.93 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

- - - - 5.1 - 6.5 - 7.1 - 8.2 - 6.9 - 7.3 - 12.1 - - - 0.2 - - - 0.3 - - - - - - - - - - - - - - - - - - - - - - -

DSO

- - - - - - 47.0 - - - 47.2 - - - 45.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- - - - - - 47.0 - - - 47.2 - - - 45.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

- - - - - - 47.0 - - - 47.2 - - - 45.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Sol-Gel Technologies Ltd., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.79 2.35 % $ 795 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.04 4.83 % $ 235 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
BioVie BioVie
BIVI
$ 1.27 -3.05 % $ 1.88 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 1.17 4.46 % $ 6.38 M chinaChina
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 0.93 -8.81 % $ 257 K usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 212.81 1.71 % $ 5 B danmarkDanmark
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.1 0.16 % $ 7.46 B australiaAustralia
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 95.03 0.95 % $ 27.2 B germanyGermany
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 26.81 1.36 % $ 1.3 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.18 -25.03 % $ 392 M israelIsrael
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.48 0.96 % $ 139 M usaUSA
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 12.37 2.06 % $ 814 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 591.15 0.02 % $ 44.8 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.53 -0.39 % $ 15.9 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 92.45 0.34 % $ 96.9 B britainBritain
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 26.83 0.94 % $ 1.73 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.0 -1.32 % $ 1.48 B britainBritain